Abstract:In a CD73-positive tumor microenvironment (TME), ATP released from apoptotic tumor cells converts to adenosine, generating an adenosine-rich immunosuppressive environment. Adenosine activates G-protein coupled receptors expressed on immune cells to achieve immune suppression, with a mechanism of action involving 1) dampening antitumor effector cells (T eff and NK cells) via adenosine engagement on A2a receptor, (2) reducing dendritic cell antigen presentation and promoting MDSC differentiation by activating A2b and A2a receptors, and (3) inducing chemotactic migration of immature plasmacytoid dendritic cells to infiltrate tumor tissue via A1 receptor. Furthermore, A1 receptor expression in certain tumors mediates an adenosine-driven tumor cell proliferation, likely through A1 receptor Gi coupling to the Hippo-YAP signal transduction pathway. Thus, pharmacologic inhibition of A2a, A2b, and A1 receptors by a triple antagonist in the context of adenosine-rich TME may represent an attractive strategy to achieve a better outcome in treating solid tumors. We discovered and characterized a novel adenosine receptor antagonist CT3021. CT3021 exhibits high binding affinity to A2a, A2b, and A1, with a Ki value of 0.37 nM, 1.76 nM, and 1.26 nM, respectively, and is selective against the A3 receptor and other 84 pharmacologically and/or toxicologically relevant targets. Schild analysis demonstrated that CT3021 is a competitive antagonist with a calculated KB value of 0.18 nM on A2a receptor in a whole cell cAMP assay in transfected HEK293 cells. In functional antagonist assays, CT3021 maintains its high potency full antagonism under an adenosine-rich TME-like condition (10-100 μM adenosine) both in transfected HEK293 cells and in isolated human T lymphocytes. CT3021 has a high oral bioavailability, a limited CNS exposure, and a favorable ADME profile. CT3021 is well tolerated in rats after repeat dosing. Further toxicology and efficacy studies are underway to explore the potential of CT3021 as a best-in-class adenosine receptor antagonist immunotherapy for the treatment of CD73 positive and A1 receptor positive solid tumors. Citation Format: Sandong Han, Nam Hee Kim, Hongmei He, Zhi Liang Chu. Discovery of CT3021, a novel potent adenosine A2a/A2b/A1 receptor triple antagonist [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 2 (Late-Breaking, Clinical Trial, and Invited s); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(7_Suppl) nr LB166.

Structural Insight into the Dual-Antagonistic Mechanism of AB928 on Adenosine A2 Receptors.

Structural Insights into Dual-Antagonize Mechanism of AB928 on Adenosine A2receptors

AB928, a Dual Antagonist of the A2aR and A2bR Adenosine Receptors, Leads to Greater Immune Activation and Reduced Tumor Growth when Combined with Chemotherapy

Subtle Structural Changes Across the Boundary Between A2AR/A2BR Dual Antagonism and A2BR Antagonism: A Novel Class of 2-Aminopyrimidine-based Derivatives.

Design, Synthesis, and Bioevaluation of 2-Aminopteridin-7(8h)-one Derivatives As Novel Potent Adenosine A2A Receptor Antagonists for Cancer Immunotherapy

Subtle Structural Changes across the Boundary between A 2A R/A 2B R Dual Antagonism and A 2B R Antagonism: A Novel Class of 2-Aminopyrimidine-Based Derivatives

Identification of New Potent A1 Adenosine Receptor Antagonists Using a Multistage Virtual Screening Approach

Discovery of Novel Dual Adenosine A1/A2A Receptor Antagonists Using Deep Learning, Pharmacophore Modeling and Molecular Docking.

Insight into the binding mode and the structural features of the pyrimidine derivatives as human A2A adenosine receptor antagonists.

Abstract LB166: Discovery of CT3021, a novel potent adenosine A2a/A2b/A1 receptor triple antagonist

Discovery of Pyridinone Derivatives As Potent, Selective, and Orally Bioavailable Adenosine A2A Receptor Antagonists for Cancer Immunotherapy

Exploring the Structural Determinants of Novel Xanthine Derivatives As A2B Adenosine Receptor Antagonists: a Computational Study

Exploring Biginelli-based scaffolds as A2B adenosine receptor antagonists: Unveiling novel structure-activity relationship trends, lead compounds, and potent colorectal anticancer agents

Adenosine A2A Receptor Antagonists for Cancer Immunotherapy

POTENT AND SELECTIVE A2AR MONOCLONAL ANTIBODY ANTAGONIST FOR THE TREATMENT OF CANCER

Structure of the Adenosine A1 Receptor Reveals the Basis for Subtype Selectivity

Structure activity relationship studies of natural product chemokine receptor CCR5 antagonist anibamine toward the development of novel anti prostate cancer agents.

A2aR on lung adenocarcinoma cells: A novel target for cancer therapy via recruiting and regulating tumor-associated macrophages

Overcoming high level adenosine-mediated immunosuppression by DZD2269, a potent and selective A2aR antagonist

Novel selective antagonist radioligands for the pharmacological study of A2B adenosine receptors

N-[6-amino-2-(heteroaryl)pyrimidin-4-yl]acetamides As A2A Receptor Antagonists with Improved Drug Like Properties and in Vivo Efficacy.